Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Diabetes
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending T
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Diabetes
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Special report
: The Fierce 50 of 2024
Seagen
Biotech
MBX Biosciences, MaaT Pharma and more—Chutes & Ladders
Metabolic disorder biotech lands industry vet as CMO. MaaT welcomes ex-Autolus leader. Former Seagen execs take Shape.
Gabrielle Masson
,
Andrea Park
Jun 28, 2024 8:30am
ASCO: It's back to the basics for cancer drug developers
Jun 5, 2024 10:55am
BioMarin hires ex-Roche leader Hubbard as CCO—Chutes & Ladders
Mar 8, 2024 9:30am
Pfizer revamps oncology R&D strategy
Feb 29, 2024 6:03pm
Are DACs the new ADCs? Seagen pays Nurix $60M to find out
Sep 7, 2023 10:35am
Seagen puts $1.6B Merck-partnered ADC on the back burner
Aug 3, 2023 12:44pm
